ANIX
Anixa Biosciences Inc
2.80$
-1.4%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 69.8% | 73.9% | 60.4% | 79.6% | 85.9% | 96.8% | 99.1% | 99.3% | 99.3% | 99.3% | 98.9% | 98.8% | |
| 37.1% | 46.8% | 44.2% | 37.9% | 47.4% | 55.5% | 67.9% | 80.3% | 40.6% | 3.6% | 5.9% | 7.7% | |
| 64.7% | 72.5% | 57.5% | 77.6% | 78.4% | 92.8% | 95.8% | 98.5% | 97.6% | 93.4% | 92.3% | 94.4% | |
| 4.4% | – | – | – | 4.8% | 1.1% | 0.0% | – | 0.2% | 1.1% | 0.8% | 0.0% | |
| 0.0% | 0.0% | – | 0.0% | 0.0% | -37.3% | -27.9% | – | -0.2% | – | – | – | |
| 0.1% | 0.5% | 2.8% | 0.6% | 1.1% | 3.2% | 0.6% | 0.7% | 0.7% | – | – | – | |
| 0.0% | 0.0% | – | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 30.1% | 25.7% | 36.8% | 19.8% | 13.0% | – | – | – | – | – | – | – | |
| 55.7% | 45.9% | 82.5% | 10.1% | 19.6% | 23.5% | 12.6% | 4.1% | 7.3% | 8.4% | 12.5% | 13.2% | |
| 20.0% | 6.4% | 8.3% | 10.1% | 19.6% | 23.5% | 12.6% | 3.5% | 6.7% | 7.9% | 11.6% | 12.2% | |
| – | – | – | – | – | – | 0.6% | 0.1% | 0.2% | 0.2% | 0.1% | 0.3% | |
| 6.0% | 4.0% | 6.6% | 5.5% | 9.0% | 9.3% | 2.5% | 0.4% | 0.9% | 0.8% | 2.4% | 1.0% | |
| 0.0% | 0.0% | – | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 44.3% | 54.1% | 17.5% | 89.9% | 84.3% | 83.2% | 92.7% | 97.7% | 95.5% | 95.4% | 92.6% | 94.3% | |
| -1,598.7% | -1,565.5% | -2,685.9% | -1,772.2% | -2,638.9% | -2,888.9% | -2,029.4% | -564.8% | -718.1% | -894.1% | -1,115.0% | -1,565.2% | |
| 105.7% | 103.1% | 155.3% | 138.4% | 273.3% | 314.4% | 235.2% | 78.8% | 99.9% | 121.4% | 147.7% | 201.8% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.